Roche’s Columvi Approval By US FDA Takes Bispecific Antibodies Into Fixed-Duration Therapy
Executive Summary
Roche’s second CD20xCD3 bispecific antibody approval in six months is the first bispecific with a 2:1 structural format as well as the first dosing regimen with a fixed time period.